超声引导热消融治疗复发性和持续性继发性甲状旁腺功能亢进的疗效与安全性:一项多中心回顾性研究
该多中心回顾性研究纳入2014年1月至2023年7月接受热消融的102例甲状旁腺切除或消融后复发或持续性继发性甲状旁腺功能亢进患者,中位随访30个月。87.3%的患者达到目标甲状旁腺激素水平(≤300 pg/mL),技术成功率100%,基线甲状旁腺激素≥1606 pg/mL是治疗失败的独立预测因素。
要点
- 超声引导热消融治疗复发或持续性继发性甲状旁腺功能亢进,87.3%的患者达到目标甲状旁腺激素水平(≤300 pg/mL)。
- 基线甲状旁腺激素≥1606 pg/mL是治疗失败的独立预测因素(比值比5.1,95%CI 1.1-23.1,p=0.04)。
- 严重低钙血症发生率为28.4%,补钙后未导致严重合并症;1.0%的患者出现持续性喉返神经麻痹。
核心结论
- 超声引导热消融对复发或持续性继发性甲状旁腺功能亢进安全有效,基线甲状旁腺激素≥1606 pg/mL是治疗失败的关键预测因素。
研究设计与样本
- 多中心回顾性研究,纳入2014年1月至2023年7月接受热消融的102例复发或持续性继发性甲状旁腺功能亢进患者,共174个增生的甲状旁腺腺体,中位随访30个月。
关键影像表现/征象
- 共评估102例患者(平均年龄52±12岁)的174个增生甲状旁腺腺体。
- 87.3%的患者达到目标甲状旁腺激素水平(≤300 pg/mL)。
- 与基线相比,甲状旁腺激素、钙、磷和碱性磷酸酶水平均显著降低(p<0.05)。
- 技术成功率为100%。
- 主要并发症:1例(1.0%)患者消融后出现持续性喉返神经麻痹;29例患者发生严重低钙血症,补钙后未导致严重合并症。
诊断标准与关键数值
- 主要终点为随访结束时达到目标甲状旁腺激素水平(≤300 pg/mL)的患者比例,结果为87.3%。
- 治疗失败的独立预测因素为基线甲状旁腺激素≥1606 pg/mL(比值比5.1,95%CI 1.1-23.1,p=0.04)。
临床应用与阅片要点
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: To evaluate the long-term efficacy and safety of Ultrasound (US)-guided percutaneous thermal ablation for recurrent or persistent secondary hyperparathyroidism (SHPT) and identify predictors of treatment failure.
MATERIALS AND METHODS: From January 2014 to July 2023, 102 patients with recurrent or persistent SHPT after parathyroidectomy or ablation received thermal ablation. The median follow-up period was 30 months. The primary endpoint was the proportion of participants who achieved target parathyroid hormone (PTH) levels (≤ 300 pg/mL) at the end of follow-up. The secondary endpoints were the mean changes in levels of PTH, calcium, phosphorus, and alkaline phosphatase (ALP) from baseline; the technical success rate; and complications. Univariate and multivariate logistic regression analyses were performed to identify independent prognostic factors affecting the prognosis of ablation.
RESULTS: A total of 102 participants (mean age, 52 ± 12 years) with 174 hyperplastic parathyroid glands were evaluated. Overall, 87.3% of the participants achieved the target PTH level. Compared to baseline, significant reduction was achieved in PTH, calcium, phosphorus, and ALP levels (p < 0.05). The technical success rate was 100%. For major complications, one (1.0%) participant experienced persistent laryngeal nerve paralysis after ablation, and severe hypocalcemia occurred in 29 participants but did not result in serious comorbidities following calcium supplementation. The only independent predictor of treatment failure was baseline PTH ≥ 1606 pg/mL (odds ratio, 5.1; 95% CI: 1.1-23.1; p = 0.04).
CONCLUSIONS: US-guided thermal ablation is safe and effective for recurrent or persistent SHPT. Baseline PTH ≥ 1606 pg/mL is a key predictor of treatment failure.
KEY POINTS: Question Recurrent/persistent SHPT lacks safe, minimally invasive therapies, while traditional repeat surgery poses high complication risks due to fibrosis and anatomical distortion. Findings The study demonstrated 87.3% in achieving target PTH levels. The incidence of severe hypocalcemia reached 28.4%. Clinical relevance This pioneering multicenter study with a large sample size demonstrates the long-term effectiveness and safety of US-guided percutaneous thermal ablation for treating recurrent and persistent SHPT. It offers a viable nonsurgical alternative for managing this condition.
引用
- Liu Y, Wu S, Peng C, et al. Efficacy and safety of thermal ablation for the treatment of recurrent and persistent secondary hyperparathyroidism: a multicenter retrospective study. Eur Radiol. 2025. PMID: 40770142. doi:10.1007/s00330-025-11862-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。